ACTLung™

ACTLung™

Precision Medicine for Frontline Lung Cancer Treatment Selection

Helps Newly Diagnosed Lung Cancer Patients to Rapidly Obtain First-Line Targeted Therapy Opportunity

In the medical journey of cancer treatment, precision medicine is recognized as a modern and favored way for healthcare system to take care of cancer patients more easily. Challenges of identifying the right drug to every cancer patient while new drugs are emerging for specific genomic mutations can be tackled strategically by having cancer patients' unique cancer genomic profiles. The acceleration of oncology drug approvals and the modernization of clinical trials with biomarker-based patients have progressed well as US FDA committed from 2018. The wave of precision medicine also increases approvals of companion diagnostics, bringing ACT Genomics' genomic profiling service on the waiting list of US FDA approval.

 

Why You Need to Know About Precision Medicine

Top global pharma companies fasten the pace to conduct clinical trials of precision medicine, which requires cancer patients' genomic information via genomic profiling. This evolution affects most hospitals, so you need to get prepared for the genomic profiling if you are always looking for a new treatment.

 

How to Make Sure the Bull's Eye is Targeted in Your Treatment?

When it comes to a big decision in life, you can't be careful enough, including your targeted therapy. There are often more than one target in tumor, and if you shoot them with a strategy rather than one guesswork after another can often make tumor into controlled, while most people don't realize the difference and lose the chance in the beginning. Cancer genomic profiling enables major targets to be revealed all at once such as EGFR, ALK, ROS1…etc, and by identifying the driver gene, you can target at the bull's eye and increase chance of having a successful treatment.

Prevalence-of-Driver-Mutations-in-NSCLC

Common Problems in Lung Cancer Treatment

∙ Chemotherapy and surgery are the only options according to NCCN guidelines or single-gene test result
∙ Complicated and metastases, hard to know the appropriate drugs
∙ Ineffective treatment, and cancer relapse after targeted therapy
∙ Pursue for immunotherapy, targeted therapy and wondering the effect

 

Diagnostic Solutions for Newly Diagnosed Lung Cancer Patients

Through Next Generation Sequencing (NGS), ACTLung™ targeted genomic profiling decodes 13 lung cancer-related genes to map drug options via clinical guidelines, enable more treatment strategies with higher success rate.

 

Targeted Genomic Profiling can Bring Treatment Advantages as Follows

✔ More humanized process: Avoid multiple biopsies and time cost of single-gene test, few specimens required for various fusion gene detection at once.

✔ More ideal treatment: Find proper targeted options

✔ Plan medical budget more intelligently: Evaluate options before treatment according to genomic information, to ensure success rate and avoid waste of medical budget. 

Type of patients
∙ Non-small cell lung cancer (NSCLC)
∙ Newly diagnosed and metastatic cancer 

Specimen requirements
Tumor tissue (FFPE)

Turnaround time
8 working days* 

*starting from the date of receipt of approved samples at our CAP-accredited laboratory        
Image

More Stories

ACT Genomics provides the best precision medicine service to every patient every day. Providing patients with the ideal testing experience is our goal. Below, you will find stories from real ACT Genomics patients — about their experiences. We hope these will give you more of an idea of what to expect when you have our test for your needs.

Read More